Skip to main content
MAYNE PHARMA GROUP LIMITED logo

MAYNE PHARMA GROUP LIMITED — Investor Relations & Filings

Ticker · MYX ISIN · AU000000MYX0 LEI · 549300VIRDEN0N4MJG59 ASX Manufacturing
Open in API
Filings indexed 1,121 across all filing types
Latest filing 2017-10-19 AGM Information
Country AU Australia
Listing ASX MYX

About MAYNE PHARMA GROUP LIMITED

https://www.maynepharma.com

Mayne Pharma Group Limited is a specialty pharmaceutical company focused on the development and commercialization of branded and generic medicines. The company operates through specialized segments including Women's Health and Dermatology. Its Women's Health portfolio features innovative contraceptive solutions, while the Dermatology division provides a broad range of treatments for various skin conditions. Beyond its product portfolio, the company provides contract development and manufacturing services (CDMO), leveraging proprietary drug delivery technologies to produce complex oral and topical dosage forms. The organization focuses on high-growth specialty markets, aiming to deliver differentiated therapeutic options and improve patient outcomes through technical excellence and strategic commercialization.

Recent filings

Filing Released Lang Actions
Notice of Annual General Meeting/Proxy Form 10 pages 2.9MB
AGM Information Classification · 100% confidence The document is titled 'Notice of Annual General Meeting' and includes details about the date, time, and place of the AGM. It outlines the business to be conducted at the meeting, including receiving and considering the Directors' Report, Financial Statements, and Independent Auditor's Report for the year ended 30 June 2017. It also includes resolutions for the election and re-election of directors, adoption of the remuneration report, and share issuance approvals. The document contains proxy voting instructions and explanatory information related to the AGM agenda items. There is no actual financial data or full report content included; rather, it is a notice and agenda for the AGM. Therefore, this document fits the category of AGM Information (AGM-R).
2017-10-19 English
2017 Annual Report 96 pages 4.2MB
Annual Report Classification · 100% confidence The document is titled 'Annual Report 2017' and contains detailed sections typical of an annual report, including a Chairman's Letter, CEO Review, Directors' Report, Remuneration Report, Auditor's Independence Declaration, Corporate Governance, full consolidated financial statements, notes to the financial statements, Directors' Declaration, and Independent Auditor's Report. It also includes comprehensive business highlights, financial data, and strategic information. The document length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement or summary. Therefore, this document fits the definition of an Annual Report (10-K). FY 2017
2017-10-18 English
2017 Corporate Governance Statement 13 pages 348.8KB
Governance Information Classification · 95% confidence The document is titled 'CORPORATE GOVERNANCE STATEMENT' and discusses the Board of Directors' responsibilities, composition, independence, nomination, appointment, meetings, and performance review. It references compliance with ASX Corporate Governance Council Principles and Recommendations and includes detailed governance policies and charters. There is no financial data, earnings information, or audit results presented. The content focuses entirely on governance practices and board structure, which aligns with the definition of Governance Information (CGR). The document length is substantial (15,000 characters), indicating it is a full statement rather than a brief announcement. Therefore, the appropriate classification is Governance Information (CGR).
2017-10-18 English
Appendix 4G 14 pages 346.3KB
Governance Information Classification · 95% confidence The document is titled 'Appendix 4G' and references ASX Listing Rules 4.7.3 and 4.10.3, which pertain to corporate governance disclosures. It includes a key to disclosures aligned with the Corporate Governance Council Principles and Recommendations for the financial year ended 30 June 2017. The document is a corporate governance statement approved by the board and includes detailed disclosures about governance practices, board roles, nomination committees, diversity policies, and evaluation processes. It references the annual report and website locations for further information but itself is a standalone governance disclosure document. This matches the definition of a Governance Information (CGR) filing, which details the company's internal rules, board structure, and governance practices. The document length (15,000 characters) and content confirm it is a full governance report, not merely an announcement or certification. Therefore, the correct classification is CGR with high confidence.
2017-10-18 English
Appendix 3B 9 pages 690.4KB
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 3B' and is described as a 'New issue announcement, application for quotation of additional securities and agreement.' It contains detailed information about the issuance of new shares, including the number of securities issued, issue price, terms, and application for quotation on the ASX (Australian Securities Exchange). The document also includes details about employee options issued under an employee share option plan. The content is regulatory in nature, focused on the announcement and application for quotation of new securities rather than a financial report or earnings release. Appendix 3B is a standard form used in Australian stock exchange filings to announce new share issues and related capital changes. Therefore, this document fits the category of Share Issue/Capital Change (SHA). The document length is substantial (over 13,000 characters), indicating it is not a mere announcement of a report but the actual filing of the share issue details.
2017-10-10 English
Mayne Pharma adds two products to its Australian portfolio 2 pages 431.5KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated 15 Sep 2017 from Mayne Pharma about receiving Therapeutic Goods Administration (TGA) approval for two specialty pharmaceutical products and their recent launch. It discusses product details, market potential, and sales strategy. There are no financial statements, regulatory certifications, or detailed financial performance data. The content is a corporate announcement about product approvals and launches, which fits the category of Capital/Financing Update (CAP) as it relates to business growth and product portfolio expansion rather than a financial report or regulatory filing. The document length is 5569 characters, which is sufficient for a detailed announcement but does not contain financial results or management discussion. Therefore, the best classification is CAP with high confidence.
2017-09-14 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.